Trial Profile
A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Pembrolizumab (Primary) ; Anastrozole
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 08 Mar 2024 This trial has been Completed in Italy, According to European Clinical Trials Database record.
- 28 Sep 2023 Planned End Date changed from 20 Sep 2023 to 31 Dec 2024.
- 08 Aug 2022 Planned End Date changed from 29 Oct 2022 to 20 Sep 2023.